Skip to main content
Veterinary Medicines

NOBILIS REO INAC

Authorised
  • Avian reovirus, strain 2408, Inactivated
  • Avian reovirus, strain 1733, Inactivated

Product identification

Medicine name:
НОБИЛИС РЕО ИНАК
NOBILIS REO INAC
Active substance:
  • Avian reovirus, strain 2408, Inactivated
  • Avian reovirus, strain 1733, Inactivated
Target species:
  • Chicken (chick)
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Avian reovirus, strain 2408, Inactivated
    ≥ 7.4 log2 ELISA units
  • Avian reovirus, strain 1733, Inactivated
    ≥ 7.4 log2 ELISA units
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Chicken (chick)
  • Subcutaneous use
    • Chicken (chick)
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AA04
Authorisation status:
  • Valid
Authorised in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • INTERVET INTERNATIONAL B.V.
Responsible authority:
  • Bulgarian Agency For Food Safety
Authorisation number:
  • 0022-1733-28.03.2012
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 8/04/2022

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 8/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."